Stocktoria
Absci Corp ABSI
Nasdaq · stock · Services-Commercial Physical & Biological Research · website · IPO 2021-07-22
Absci Corp financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.8M | $4.5M | $5.7M | $5.7M | $4.8M | $4.8M |
| R&D expense | $81.4M | $63.9M | $48.1M | $58.9M | $44.6M | $11.4M |
| SG&A expense | $35.1M | $36.2M | $37.8M | $40.6M | $28.8M | $5.5M |
| Operating income | -$120.3M | -$108.9M | -$115.5M | -$106.8M | -$75.2M | -$13.3M |
| Interest expense | — | — | $1.0M | $972,000 | $3.4M | $634,000 |
| Income tax | $69,000 | $70,000 | $100,000 | -$461,000 | -$8.9M | $0 |
| Net income | -$115.2M | -$103.1M | -$110.6M | -$104.9M | -$101.0M | -$14.4M |
| EPS (diluted) | $-0.84 | $-0.94 | $-1.20 | $-1.15 | $-2.08 | $-3.19 |
| Operating cash flow | -$92.9M | -$72.4M | -$64.6M | -$81.3M | -$60.6M | -$11.0M |
| Free cash flow | -$94.0M | -$72.8M | -$65.5M | -$97.5M | -$98.6M | -$13.2M |
| Cash & equivalents | $20.0M | $41.2M | $72.4M | $60.0M | $252.6M | $69.9M |
| Total assets | $216.3M | $213.6M | $217.3M | $321.0M | $426.2M | $88.6M |
| Total liabilities | $26.8M | $34.5M | $41.1M | $46.6M | $60.1M | $21.6M |
| Shareholders' equity | $189.4M | $179.1M | $176.2M | $274.4M | $366.1M | -$89.4M |
Growth · year-over-year · Revenue CAGR -10.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -38.2% | -20.7% | -0.5% | +20.2% | +0.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.